Virology Follow up Study in Subjects Previously Treated With Telaprevir

Telaprevir Open-Label Study in Co-Infected Patients

NCT01500616 ·Status: COMPLETED ·Phase: PHASE3

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

NCT01054573 ·Status: COMPLETED ·Phase: PHASE3

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms

NCT01641094 ·Status: COMPLETED

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432 ·Status: COMPLETED ·Phase: PHASE1

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847 ·Status: COMPLETED ·Phase: PHASE2

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963 ·Status: TERMINATED ·Phase: PHASE3

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

NCT01253551 ·Status: COMPLETED ·Phase: PHASE1

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

NCT01598090 ·Status: COMPLETED ·Phase: PHASE3

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760 ·Status: COMPLETED ·Phase: PHASE3

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

NCT02753699 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

NCT00528528 ·Status: COMPLETED ·Phase: PHASE2

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

NCT01571583 ·Status: COMPLETED ·Phase: PHASE3

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C

NCT01980290 ·Status: COMPLETED

Telaprevir in Genotype 3 HCV

NCT02087111 ·Status: COMPLETED ·Phase: PHASE4

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

NCT00561015 ·Status: COMPLETED ·Phase: PHASE2

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01415141 ·Status: WITHDRAWN ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

NCT01516918 ·Status: COMPLETED ·Phase: PHASE2

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

NCT00591214 ·Status: COMPLETED ·Phase: PHASE1

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

NCT00420784 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

NCT00983853 ·Status: COMPLETED ·Phase: PHASE2

Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

NCT01582035 ·Status: COMPLETED ·Phase: PHASE1

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

NCT02465203 ·Status: TERMINATED ·Phase: PHASE3

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631 ·Status: COMPLETED ·Phase: NA